Enzalutamide shows positive outcome in TERRAIN trial

A media release issued today by Medivation and Astellas Pharma, based on data presented at the European Association of Urology meeting in Madrid, Spain, states that enzalutamide appears to extend progression-free survival (PFS) better than bicalutamide in the randomized, Phase II TERRAIN trial. … READ MORE …

Prostvac Phase III trial results in mCRPC “by early 2017″

According to a Reuters report issued early this morning, the CEO of Barvarian Nordic has stated publicly that the company expects results of Phase III trials of Prostvac VF in men with metastatic, castration-resistant prostate cancer (mCRPC) by early 2017 or perhaps earlier. … READ MORE …

Prostvac + ipilimumab shows promise in management of mCRPC

Results from a small trial of Barvarian Nordic’s investigational drug Prostvac — used in combination with Bristol-Myers Squibb’s ipilimumab (Yervoy) — appear to have shown relatively dramatic effects in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Efavirenz not effective in the treatment of mCRPC

Some time ago a group of French researchers initiated a Phase II trial of efavirenz (Sustiva®) in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Guidelines and the current treatment of mCRPC

The December 1 issue of The ASCO Post contains two articles that will be of interest to many patients with progressive disease and their family members. … READ MORE …

Who’s actually dying of prostate cancer (in France) today?

A newly published paper from a French research group has provided some interesting data on which patients actually die of prostate cancer in the modern, post-PSA era. … READ MORE …

Cabozantinib not sufficiently effective in treatment of mCRPC

According to a media release from Exelixis in the past hour, it appears that we have seen the end of all attempts to develop cabozantinib as a treatment for metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,253 other followers